Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands

被引:13
|
作者
Freudenburg-de Graaf, W. [1 ,2 ]
Knol, M. J. [3 ]
van der Ende, A. [1 ,2 ]
机构
[1] Univ Amsterdam, Dept Med Microbiol & Infect Prevent, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Netherlands Reference Lab Bacterial Meningitis, Amsterdam, Netherlands
[3] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control Netherlands, Bilthoven, Netherlands
基金
英国惠康基金;
关键词
Neisseria meningitidis; 4CMenB vaccine; Whole-genome sequencing; gMATS; B VACCINE; BACTERICIDAL ANTIBODIES; PERSISTENCE; AGE; IMMUNOGENICITY; IMMUNIZATION; ADOLESCENTS; INFANTS; STRAIN;
D O I
10.1016/j.vaccine.2020.10.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease in Europe. In the absence of a conjugate serogroup B vaccine, a subcapsular 4CMenB vaccine was developed. Data on 4CMenB vaccine efficacy is still limited. Recently, genomic MATS (Meningococcal Antigen Typing System) was developed as a tool to predict strain coverage, using vaccine antigens sequence data. We characterized all invasive meningococcal isolates received by the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) in two epidemiological years 2017-2019 using whole-genome sequencing and determined serogroup, clonal complex (cc) and estimated 4CMenB vaccine coverage by gMATS. Of 396 cases of invasive meningococcal disease, corresponding to an incidence of 1.22 cases/10(5) inhabitants, 180 (45%) were serogroup W, 155 (39%) serogroup B, 46 (12%) serogroup Y, 10 (3%) serogroup C, 2 non-groupable (0.5%) and 3 (0.7%) unknown. The incidence was the highest among 0-4 years olds (4 cases/10(5) inhabitants), and 57/72 (79%) of these cases were serogroup B. Serogroup W predominated among persons 45 years of age or older with 110/187 (59%) cases. Serogroup B isolates comprised 11 different clonal complexes, with 103/122 (84%) isolates belonging to 4 clonal complexes: cc32, cc41/44, cc269 and cc213. In contrast, serogroup W isolates were genetically similar with 95% belonging to ccl 1. Of 122 serogroup B isolates, 89 (73%; 95% CI: 64-80%) were estimated to be covered by 4CMenB and the degree of coverage varied largely by clonal complex and age. Among the 0-4 year olds, 25 of 43 (58%; 95% CI: 43-72%) MenB isolates were estimated to be covered. Since the coverage of the 4CMenB vaccine is dependent on circulating clonal complexes, our findings emphasize the need for surveillance of circulating meningococcal strains. In addition, estimation of age specific coverage is relevant to determine the right target age group for vaccination. (C) 2020 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:7850 / 7857
页数:8
相关论文
共 50 条
  • [31] A new multicomponent vaccine (4CMenB) to protect against serogroup B meningococcal disease. Part 2: Safety and tolerability
    Zwiauer, K. F. M.
    BrOKer, M.
    Banzhoff, A.
    PADIATRIE UND PADOLOGIE, 2014, 49 : 13 - 19
  • [32] Meningococcal B Vaccination (4CMenB) in Infants and Toddlers
    Esposito, Susanna
    Tagliabue, Claudia
    Bosis, Samantha
    JOURNAL OF IMMUNOLOGY RESEARCH, 2015, 2015
  • [33] Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Neisseria meningitidis Isolated from 2009 to 2013 in the Republic of Ireland
    Mulhall, Robert M.
    Bennett, Desiree
    Cunney, Robert
    Borrow, Ray
    Lucidarme, Jay
    Findlow, Jamie
    Jolley, Keith A.
    Bray, James
    Maiden, Martin C. J.
    Moschioni, Monica
    Serino, Laura
    Stella, Maria
    Medini, Duccio
    MSPHERE, 2018, 3 (04):
  • [34] The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens
    Serruto, Davide
    Bottomley, Matthew J.
    Ram, Sanjay
    Giuliani, Marzia M.
    Rappuoli, Rino
    VACCINE, 2012, 30 : B87 - B97
  • [35] The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy
    Rollier, Christine S.
    Dold, Christina
    Marsay, Leanne
    Sadarangani, Manish
    Pollard, Andrew J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (01) : 131 - 142
  • [36] The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans
    Toneatto, Daniela
    Ismaili, Shevqet
    Ypma, Ellen
    Vienken, Kay
    Oster, Philipp
    Dull, Peter
    HUMAN VACCINES, 2011, 7 (06): : 646 - 653
  • [37] Meningococcal B vaccine (4CMenB): the journey from research to real world experience
    Rappuoli, Rino
    Pizza, Mariagrazia
    Masignani, Vega
    Vadivelu, Kumaran
    EXPERT REVIEW OF VACCINES, 2018, 17 (12) : 1111 - 1121
  • [38] Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB): a meta-analysis
    Flacco, M. E.
    Manzoli, L.
    Rosso, A.
    Marzuillo, C.
    Bergamini, M.
    Stefanati, A.
    Villari, P.
    Ricciardi, W.
    Ioannidis, J. P.
    Contopoulos-Ioannidis, D. G.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2017, 27
  • [39] Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK
    Ladhani, Shamez N.
    White, Peter J.
    Campbell, Helen
    Mandal, Sema
    Borrow, Ray
    Andrews, Nick
    Bhopal, Sunil
    Saunders, John
    Mohammed, Hamish
    Drisdale-Gordon, Lana
    Callan, Emma
    Sinka, Katy
    Folkard, Kate
    Fifer, Helen
    Ramsay, Mary E.
    LANCET INFECTIOUS DISEASES, 2024, 24 (09): : e576 - e583
  • [40] EFFECTIVENESS OF THE 4CMENB VACCINE AGAINST GONORRHOEA AMONG YOUNG PEOPLE
    Rusconi, Stefano
    Tan, Rayner K. J.
    Ceccherini-Silberstein, Francesca
    SEXUALLY TRANSMITTED INFECTIONS, 2022, 98 (07) : 547 - 548